The city of San Antonio, Texas, currently has 32 active clinical trials seeking participants for Diabetes research studies.
SGLT2 Inhibitors, Ketogenesis, and Ketoacidosis
Recruiting
The purpose of this study is to examine the effect of empagliflozin, with and without pancreatic clamp, on endogenous (hepatic) glucose production (EGP, or 6,6, D2-glucose), gluconeogenesis (D2O), lipolysis (U-2H-glycerol), ketogenesis (13C-palmitate conversion to 3-betahydroxybutyrate), and norepinephrine turnover (3H-NE) in type 2 diabetes subjects.
Gender:
All
Ages:
Between 30 years and 75 years
Trial Updated:
10/18/2023
Locations: Texas Diabetes Institute/UH, San Antonio, Texas
Conditions: Type 2 Diabetes, Type 1 Diabetes
Quantifying Hepatic Mitochondrial Fluxes in Humans
Recruiting
In this study the investigators will quantitate hepatic mitochondrial fluxes in T2D patients with NAFL and NASH before and after 16-weeks treatment with the insulin sensitizer pioglitazone
Gender:
All
Ages:
Between 18 years and 80 years
Trial Updated:
08/21/2023
Locations: Texas Diabetes Institute - University Health System, San Antonio, Texas +1 locations
Conditions: Non-Alcoholic Fatty Liver Disease, Type 2 Diabetes, Mitochondrial Metabolism Disorders
XW014 in Healthy Subjects and Patients With Type 2 Diabetes Mellitus (T2DM)
Recruiting
This is a Phase 1, randomized, double-blind, placebo-controlled, first-in-human (FIH) study to evaluate the safety, tolerability, food effect (FE), pharmacokinetics (PK), and pharmacodynamics (PD) of orally administered XW014 in healthy participants and patients with T2DM. This study will consist of 3 parts: a Single Ascending Dose (SAD) part in healthy subjects (Part A), and Multiple Ascending Dose (MAD) parts in healthy subjects with elevated BMI (Part B) and patients with T2DM (Part C).
Gender:
All
Ages:
Between 18 years and 70 years
Trial Updated:
08/14/2023
Locations: ICON - Early Development Services, San Antonio, Texas
Conditions: Type 2 Diabetes Mellitus
Pre-diabetes in Subject With Impaired Fasting Glucose (IFG) and Impaired Glucose Tolerance (IGT)
Recruiting
HYPOTHESIS: Impaired glucose tolerance (IGT) and impaired fasting glucose (IFG) have distinct pathophysiologic etiologies. Therefore, therapeutic interventions designed to correct the specific underlying pathogenic abnormalities in IGT and IFG will be required to optimally prevent the progressive beta cell failure and development of overt type 2 diabetes.
Gender:
All
Ages:
Between 18 years and 65 years
Trial Updated:
08/02/2023
Locations: The University of Texas Health Science Center at San Antonio, San Antonio, Texas
Conditions: Diabetes Mellitus, Type 2, Impaired Glucose Tolerance (IGT), Impaired Fasting Glucose (IFG)
Pioglitazone on Heart Failure in Type-2 Diabetes Mellitus Participants
Recruiting
Our goal of the study is to learn the effects of the diabetes medication named Pioglitazone, in type-2 diabetic obese participants with Heart failure. The main question it aims to answer are: To demonstrate that impaired mitochondrial function leading to reduced ATP generation plays a key pathophysiologic role in the development of heart failure with preserved ejection fraction (HFpEF) in obese type 2 diabetic (T2D) individuals. To demonstrate that pioglitazone, improves diastolic (as well as s... Read More
Gender:
All
Ages:
Between 30 years and 70 years
Trial Updated:
07/13/2023
Locations: Texas Diabetes Institute/UH, San Antonio, Texas
Conditions: Type 2 Diabetes Mellitus in Obese, Heart Failure With Preserved Ejection Fraction
Enhance Study: Evaluation of Accuracy and Safety of the Eversense CGM System With Enhanced Features
Recruiting
A Prospective, Multicenter Evaluation of Accuracy and Safety of the Eversense CGM System with Enhanced Features. The purpose of this clinical investigation is to evaluate the accuracy of the Eversense 524 Continuous Glucose Monitoring System (Eversense 524 CGM System) and ROME CGM System with next generation feature enhancements compared to reference glucose measurements in adults 18 years of age and older with diabetes. The investigation will also evaluate safety of the Eversense 524 CGM System... Read More
Gender:
All
Ages:
14 years and above
Trial Updated:
04/24/2023
Locations: Clinical Trials of Texas, LLC. (CTT), San Antonio, Texas
Conditions: Diabetes Mellitus, Diabetes Mellitus, Type 1, Diabetes Mellitus, Type 2
Personalized Behavioral Nutrition Intervention in Older AAs With T2D
Recruiting
The rapid growth rate and unique challenges as a new immigrant group call for a better understanding of the social and health needs of the older Asian Americans (AAs) population. Overwhelming numbers of AAs, a fast-growing first-generation immigrant group, suffer from type 2 diabetes (T2D) and its consequences of poorly controlled blood glucose. For the older AAs, there are higher prevalence rates, worse diabetes control, and higher rates of complications due to limited English proficiency and h... Read More
Gender:
All
Ages:
65 years and above
Trial Updated:
04/17/2023
Locations: The University of Texas Health Science Center at San Antonio, San Antonio, Texas
Conditions: Type 2 Diabetes
Evaluation of the Safety and Effectiveness of the Dexcom Glucose Monitoring (CGM) System
Recruiting
Evaluation of the Safety and Effectiveness of the Dexcom Glucose Monitoring (CGM) System
Gender:
All
Ages:
2 years and above
Trial Updated:
11/25/2020
Locations: Endeavor Clinical Trials, San Antonio, Texas
Conditions: Diabetes Mellitus